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Abstract
Background: HIV-load decrease and suppression over time is associated with consistent adherence to antiretroviral
therapy (ART). Our study aimed to evaluate the difference in viral load and adherence of patients treated with a
combination of either Tenofovir (TDF), Lamivudine (3TC) and Efavirenz (EFV) or TDF / Zidovudine (AZT), 3TC and
Nevirapine (NVP) regimens at 24 and 48 weeks.
Methods: A longitudinal study was conducted from May 2016 to June 2017 among 256 HIV infected adult patients
who were enrolled at two approved treatment hospitals in Yaoundé, before the start of first-line ART. Whole blood
samples were collected using standard operating procedures. HIV-loads were determined by a quantitative
RealTime PCR assay. Adherence was evaluated by pharmacy refill data records. Statistical analyses were performed
using the PRISM 5.0 software.
Results: Off the 256 HIV infected patients enrolled, 180 (70%) patients completed the study and 76 (30%) patients
were lost to follow-up. The success rate in achieving viral load < 40 copies/ml was 1.8 times higher with the EFV
regimen at 24 weeks and was 1.2 times higher in the NVP regimen at 48 weeks. At 48 weeks the treatment failure
rate was 12.0 and 40.0% in patients on EFV and the NVP regimen, respectively. The rate of adherence varied in both
ART based regimens with 84.0 to 74.0% for EFV and 65.5 to 62.5% for NVP, at 24 and 48 weeks respectively.
Conclusion: In our study and setting, the rate of viral load decrease was higher in the NVP based regimen than
with the EFV regimen. The adherence rate to ART was higher in the EFV regimen, compared to the NVP regimen.
This adds to evidence that the EFV regimen is the preferred ART combination for non-nucleoside reverse
transcriptase inhibitors (NNRTIs).
Keywords: HIV-load, Adherence, Efavirenz, Nevirapine, HIV infected adult
* Correspondence: bhycenta@gmail.com
1Center for the Study and Control of Communicable Diseases (CSCCD),
Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1,
Yaoundé, Cameroon
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chendi et al. BMC Infectious Diseases          (2019) 19:194 
https://doi.org/10.1186/s12879-019-3824-7
Background
The introduction of antiretroviral therapy (ART) world
wide as treatment for HIV infections has greatly reduced
mortality and morbidity among patients living with HIV
[1, 2]. The first-line therapeutic scheme used in Cameroon
involves the combination of two nucleoside reverse tran-
scriptase inhibitors (NRTIs): Zidovudine (AZT) or Teno-
fovir (TDF) and Lamivudine (3TC); and a non-nucleoside
reverse transcriptase inhibitor (NNRTI): either Efavirenz
(EFV) or Nevirapine (NVP) [3]. Achieving favorable HIV
treatment outcomes is a major challenge, particularly due
to non-adherence and the development of strains harbor-
ing resistance associated mutations (RAMs) [4].
The standard approach for monitoring treatment out-
comes in patients on ART depends on the measurement
of HIV-load over time. According to the WHO guide-
lines, virological failure is observed when patients sus-
tain a viral load > 1000 copies/ml after 6 to 12 months of
ART. The persistent high viral load in most cases is due
to non-adherence [5].
Studies from low- and middle-income countries have
shown measuring adherence is more likely to predict
virological failure than clinical and immunological cri-
teria. In Cameroon, poor adherence, treatment interrup-
tion due to dosage and the loss to follow-up are factors
reported most likely to influence virological failure re-
sponses. In spite of adherence being found to be an im-
portant factor in influencing treatment outcome, there
are no standard guidelines for its measurement [6–10].
Cameroon follows and strictly applies the WHO ART
guidelines with the EFV regimen (TDF, 3TC and EFV)
taken as a single dose daily and the NVP regimen (AZT/
TDF, 3TC and NVP) taken twice daily [3]. Though the
EFV regimen was considered preferential over NVP in
some studies; there are no clear-cut criteria or guidelines
used in choosing either of the two regimens for patients
at initiation of ART. This has raised many concerns over
the correct ART combination to be provided at which
time point. In addition, Cameroon is a resource limited
country where historical ART access and economic and
cultural limitations may still influence the optimal per-
formance of ART. It is thus imperative to provide evi-
dence with local data that will guide the clinicians to
focus on the most effective treatment combinations. We,
therefore, conducted a longitudinal study over 48 weeks
on HIV-infected patients before receiving the two
NNRTI-based regimens in Yaoundé, Cameroon.
Methods
Setting
A longitudinal cohort study was conducted from May 2016
to June 2017 to evaluate ART outcome at two approved
treatment and care centers for HIV in Yaoundé (Yaoundé
Central Hospital and “Centre Hospitaliered’Essos”). We
determined the difference in viral load and assessed adher-
ence in HIV adult patients.
Study participants and data collection
The study population consisted of 256 consenting HIV in-
fected adult patients who were all treatment naïve at the
beginning of the study. Patients were initiated on either the
combination of TDF/3TC/EFV (300mg/300mg/600mg)
taken as a single dose daily or AZT/3TC/NVP (300mg/
150mg/200mg) taken twice daily. Questionnaires were ad-
ministered to collect socio-demographic data and treat-
ment information. Whole blood (5ml) was collected in
Ethylenediaminetetraacetic acid (EDTA) collection tubes
from each patient for viral load testing at baseline (prior to
the start of ART), 24 and 48 weeks, using standard proce-
dures. Laboratory analyses were done at the Center for the
Study and Control of Communicable Diseases (CSCCD) of
the University of Yaoundé I.
HIV-load testing
RNA viral load testing were performed before the start of
ART and at 24 and 48 weeks of treatment using an auto-
mated RealTime PCR assay:CobasAmpliprep/Cobas-
Taqman 96 platform (Roche Diagnostics, Mannheim,
Germany). Plasma samples were analyzed based on
the manufacturer’s instruction. The detection limit of
the assay was < 40 copies per ml.
Measurement of adherence
There are no standard guidelines for the measurement
of adherence to ART. Drug screening for adherence was
evaluated based on pharmacy refill data records report-
ing the number of patients who came for their drugs on
their respectful appointment dates. This enabled us to
evaluate the number of patients who continued one of
either EFV or NVP containing first-line NNRTI regi-
mens during the study period as being adherent to ART.
We classified patients’ rate of adherence as being good, fair,
poor or non-adherent based on a rating scale we developed
with a define limit of 40% and interval of 20%. The number
of patients who continued treatment was converted to per-
centage in order obtain the rate of adherence. A rate ≤ 40%
was considered non-adherent to ART, 40–60% as poor
adherence, 60–80% as fair adherence and ≥ 80% as good
adherence. At baseline, all patients were considered adher-
ent at 100% to their respective ART regimens.
Statistical analyses
Data were recorded in a Microsoft Excel sheet and stat-
istical analyses were performed using the Graphpad
PRISM 5.0 software package (GraphPad Software, Inc.,
La Jolla, California, USA). Descriptive statistics were
used to analyze the patient’s demographic information.
Repeated measures of the ANOVA test was computed to
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outline the mean difference in viral load. The Mann-
Whitney non-parametric tests were used to calculate the
mean difference in the level of detectable viral load.
Relative risk ratio and percentage relative effect were
used to predict the likelihood of achieving virological
suppression. Different level approach namely: good, fair,
poor and non-adherence was used to evaluate adherence
according to pharmacy records and the proportion of
patients who remained on treatment using cross contin-
gence tables. The level of significance of all analyses was
set at p < 0.05.
Results
Demographic and clinical characteristics
Of the 256 infected patients enrolled in the study, 180
(70%) patients completed the study with 76 (30%) pa-
tients lost to follow-up. Of the 180 patients, 72 (40%)
were male and 108 (56%) were female, with 100 patients
on the EFV regimen and 80 patients on the NVP regi-
men. The age of the participants ranged from 24 to 57
years, with the most representative age group ranging
from 38 to 43 years old. The characteristics of the study
population are shown in Table 1.
Outcomes of HIV-load over 48 weeks of ART
There was a statistically significant decrease in HIV-load,
from baseline to 48 weeks, among all regimens, with
p < 0.0001. The median baseline HIV-loads were 4440,
2270 and 40 copies/ml at time points 0, 24 and 48 weeks,
with semi interquartile ranges of 1976–8100, 204.8–7029
and 40–995, respective copies (Fig. 1). In both treatment
regimens, there were a decrease in the mean value of the
viral load. The HIV-load for patients on EFV at time points
0, 24 and 48 were 6871.0, 2954.8 and 335.2 copies/ml, re-
spectively. For the NVP regimen, mean viral load at time
points 0, 24 and 48 were 8546.0, 6237.3 and 715.1
copies/ml, respectively. The mean difference in viral load
at each point time was significant in patients on either regi-
men with p = 0.0011 and p = 0.0055, respectively (Fig. 2).
Virological suppression
The proportion of patients on either regimen who achieved
a viral load result < 40 copies/ml at 24 weeks and 48 weeks
were evaluated using the relative risk ratio and percentage
relative effect. The analyses showed that at 24 weeks on
ART, the possibility of achieving viral load < 40 copies/ml
among patients taking the EFV regimen was 1.7 times
higher than those on the NVP regimen (0.8). Viral
load < 40 copies/ml was observed in 26.0% (n = 28/108) of
patients on the EFV regimen as compared to 14.2% (n =
12/84) patients on the NVP regimen. Patients taking EFV
had a 75.0% increased rate in obtaining a viral load < 40
copies/ml. Patients on the NVP regimen at 48 weeks
were 1.2 times more likely to achieve a viral load of <
40 copies/ml with an increased possibility of 23.0%,
compared to patients on the EFV regimen (0.5). The
proportion of patients with viral load < 40 copies/ml
at 48 weeks was observed in 60.0% (n = 48/80) of pa-
tients on the NVP regimen and in 52.0% (n = 52/100)
of patients on the EFV regimen (Table 2).
There was a significant decrease in the mean level of de-
tectable viral load (viral load > 40 copies/ml) from 24 weeks
to 48 weeks, with p = 0.001 using the Mann-Whitney
non-parametric test. In both regimens, EFV and NVP, the
decrease in the viral load level was equally significant with
p = 0.01 and p = 0.03, respectively. In addition, an increase
in the level of undetectable viral load (viral load < 40 cop-
ies/ml) was attained from 24weeks to 48 weeks in both
regimens, with a greater increase level observed in the
NVP group (from 14.2 to 60.0%) than with the EFV group
(29.9 to 52.0%) (Fig. 3).
Table 1 Participants characteristics at 48 weeks on ART
Variable Category Frequency (%)
Outcome of participants Completed 180 (70.3%)
Lost to follow up 76 (29.6%)
Gender Female 108 (60%)
Male 72 (40%)
Age (years) Median 39
≤ 25 years 8 (4%)
26 – 31 years 20 (11%)
32–37 years 52 (29%)
38–43 years 48 (27%)
44–49 years 28 (16%)
≥ 50 years 24 (13%)
ART regimen EFV 100 (55.5%)
NVP 80 (44.4%)
Abbreviations: ART Antiretroviral therapy, EFV Efavirenz, NVP Nevirapine
Fig. 1 HIV-load over time. The Box plot shows the distribution of
viral load in copies/ml at baseline, t = 0 before treatment, at 24
weeks (t = 24) and at 48 weeks (t = 48) on ART
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Treatment failure
Sequential viral load monitoring is the recommended ap-
proach in defining treatment failure, despite its costly na-
ture. We compared patients’ viral load at 24 and 48weeks
in each treatment regimen to evaluate treatment failure.
Treatment failure was calculated based on two successive
measurements of viral load with results > 1000 copies/ml,
according to the WHO criteria. Data collected at 24 weeks
were used as the baseline and that at 48 weeks was consid-
ered as the first time point to evaluate the virological fail-
ure rate. In patients on the NVP regimen, the rate of
virological failure was higher, with 40.0%, than that of pa-
tients on the EFV regimen, with a rate of 12.0%. Twelve
patients on the EFV regimen experienced treatment fail-
ure compared to thirty-two patients on the NVP regimen.
Thus, patients on the EFV regimen were less likely to en-
counter treatment failure compared to those on the NVP
regimen (Table 3).
Adherence to ART
We evaluated the rate of adherence to ART regimens
from pharmacy refill data, taking into consideration the
number of patients still on treatment in both regimens.
From 24 weeks to 48 weeks there was a decrease in the ad-
herence rate and increase in non-adherent rate in both
regimens. The proportion decreased from 84.0% to 78.0,%
in patients taking the once-daily tablet EFV regimen and
from 65.5 to 62.5% in patients taking the twice-daily tablet
NVP regimen. The adherence rate was higher in the EFV
group compared to the NVP group at 24 and 48weeks,
despite the decreased difference observed. The proportion
of patients considered non-adherent increased from 16.0
to 22.0% in the EFV regimen and from 34.5 to 37.6% in
the NVP regimen (Fig. 4).
Age group, gender and the difference in viral load was
evaluated in relation to the rate of adherence. The age group
38–43 years was more representative among the group of
patients with adherence to the EFV regimen. The most rep-
resentative age group in the NVP regimen was 32–37 years.
Females were more adherent with either regimen. More so,
patients experiencing viral load changes were those adherent
to their respective treatment regimens. (Table 4).
Discussion
The evaluation and monitoring of the effectiveness of
ART based on HIV-load is of great importance [11]. ART
Fig. 2 Difference in viral load. The variation of viral load in both efavirenz (EFV) and nevirapine (NVP) regimens were plotted at baseline, 24 and
48 weeks over time. Each point on the graph represents the mean viral load of patients at a given point in both regimens
Table 2 viral suppression of viral load < 40 copies/ml in both regimens. The probability of achieving viral load < 40 copies/ml was
evaluated at 24 and 48 weeks in efavirenz and nevirapine regimen based on the relative risk ratio
EFV NVP
At 24 weeks At 48 weeks At 24 weeks At 48 weeks
Patients (n) 28 (26.0%) 52 (52.0%) 12 (14.2%) 48 (60%)
Cumulative incidence 0.3 0.6 0.2 0.8
Relative Risk 1.7 0.8 0.5 1.2
% relative effect 75.0% increase 18.7% decrease 43.0% decrease 23.0% increase
Abbreviations: EFV Efavirenz, NVP Nevirapine, n number of patients
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suppresses HIV-load, restores and improves immune
function, thereby enhancing the quality of life [1, 12, 13].
The maintenance of the efficiency of ART requires some
degree of high adherence, otherwise, it can inevitably lead
to virological failure [14].
In this study, we observed a 70.0% retention rate from
the 256 HIV infected adult patients recruited. This could
be related to the limiting factors of a longitudinal study,
such as lost to follow-up, change of contact, change of
environment or even death. The 70.0% retention rate
obtained was higher than that found by Dalal et al.,
(2015) and Alula et al., (2017) and raises concerns over
poor maintenance of cohorts in longitudinal studies in
Africa [15, 16]. Nevertheless, among the 30.0% lost to
follow-up individuals, the majority of the patients were
on the EFV regimen, more were men and the most rep-
resentative age group range was 32–37 and 38–43 years.
We observed an overall significant decrease (p < 0.0001)
in the mean value of HIV-load over time in both the EFV
and NVP regimens (p = 0.0011 and p = 0.0055). This de-
crease in viral load was a result of the effectiveness of
ART in preventing the replication of HIV. Our results are
in accordance with the findings of Edward et al., (2015)
who in their study in HIV-infected adults reported the ef-
fectiveness of ART in bringing about a dramatic decrease
in viral load [17]. Similar results on the effectiveness of
EFV and NVP were also obtained in a systematic review
study aimed at determining the most effective NNRTIs
when given in combination as part of ART [18].
We observed a significant increase (p = 0.0010) in the
level of viral load < 40 copies/ml throughout the study,
implying a progressive reduction in viral load at each
time point. Patients on the EFV regimen at 24 weeks of
treatment were better at achieving viral load < 40 cop-
ies/ml. At 48 weeks, patients on NVP had a better out-
come in achieving the same viral load level. These
results could be attributed to a difference in baseline
HIV-load level in each regimen before ART initiation
and treatment interruption during ART influencing the
viral load. Hence, no constant decrease in HIV-load
level. This finding is in accordance with the findings of
Wu et al., (2015), in a five year longitudinal study evalu-
ating the effectiveness of first-line ART in HIV/AIDS
patients and with the findings of Meresse et al., (2013),
reporting the impact of treatment interruption on viro-
logical response [10, 11].
Fig. 3 HIV-load suppression at 24 and 48 weeks. The level of viral load < 40 copies/ml and > 40 copies are represented as undetectable and
detectable viral load levels in the chart. Each bar represents the percentage of undetectable and detectable viral load levels in both regimens at
24 and 48 weeks of treatment
Table 3 Treatment failure compare between regimen groups. Rate of sustainable viral load level > 1000 copies/ml at 24 weeks and
at 48 weeks was calculated along side the median viral load. Virological failure rate decrease in both treatment regimens and was
high in the NVP regimen compare to EFV
ART
regimen
Rate of sustainable viral load level > 1000 copies/ml
Viral outcome at baseline Viral outcome at 24 weeks Viral outcome at 48 weeks
n Median VL (copies/ml) n Median VL (copies/ml) VFR(%) n Median VL (copies/ml) VFR(%)
EFV 80 6510 52 4440 48.1% 12 1345 12%
NVP 84 6930 64 6290 76.1% 32 1656 40%
Total 164 6930 116 6245 60.4% 44 1532 24%
Abbreviations: EFV Efavirenz, NVP Nevirapine, VFR Virological Failure Rate, VL Viral load, n number of patients
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Patients taking the EFV combination were less likely to
experience virological failure (48.0 and 12.0%), compared
to the NVP regimen group (76.0 and 40.0%) at 24 and 48
weeks, respectively. The overall failure rate (24.0%) at 48
weeks of ART could be due to non-adherence in both
treatment regimens. Similar results obtained in a cohort
study in Uganda, South Africa and in a meta-analysis
study reporting patients on EFV based regimens were less
likely to experience virological failure than patients based
on NVP regimens [19-21]. Our results are, on the con-
trary, slightly higher than that found by Zoofaly et al., in
2015 in a prospective cohort study in Cameroon reporting
a 16.0% virological failure rate at 12months. The study
suggests the association of incomplete adherence with in-
complete suppression of viral load [22].
In Cameroon till date, there are no clear-cut guidelines
for the use of administrating one of either EFV or NVP
containing first-line NNRTI regimens, despite the proven
efficacy of the EFV regimen compared to the NVP-based
regimen. While several studies in resource-rich settings
have provided evidence of increased risk of virological
failure associated with the NVP based regimen, only a few
studies have been done to verify this hypothesis in re-
source poor settings [20, 21].
In this study, we observed good and fair adherence to
ART at 24 and 48 weeks. Good adherence (81.0%) was
observed in patients on the EFV regimen and probably
resulted in the reduction in viral load. Fair adherence
(64.0%) was detected among patients on the NVP regi-
men and might be associated with the high treatment
failure. The high adherence rate in patients on the EFV
regimen compared to the NVP regimen could be attrib-
uted to the dosing frequency difference in the regimens.
Patients on the EFV regimen are administered a single
dose, easy to administer, compared to patients on the
NVP regimen taking a twice-daily dose. The good adher-
ence rate to EFV regimen is in accordance with the find-
ings of a cross-sectional survey that reported adherence
variations of between 71.0 and 93.0% [7]. Similar obser-
vations of a decrease in adherence rates were also ob-
tained in other studies reporting higher adherence with
the once-daily regimen, compared to the twice-daily regi-
men [6, 9, 23]. Our results are, however, higher than those
found in a study among Kenyan patients on long-term
ART that reported good adherence at 55.8%, fair adherence
at 22.2% and poor adherence at 22.0% [24]. Increase in
non-adherence was equally observed and closer to previous
findings performed in Cameroon. The outcome showed
poor adherence as a result of dosing frequency inconve-
niences, patients neglecting to take ART, being away from
home and concerns over privacy [4, 8, 25]. Nevertheless,
compared to our evaluation system, most of the previous
studies evaluating adherence were either based on self
report questionnaires, drug concentrations in the blood,
Fig. 4 Adherence and non-adherence to ART regimens at 24 and 48 weeks. The percentage of patients considered adherent and non-adherent
at 24 and 48 weeks, are represented in the chart. All patients on the EFV and NVP regimen were considered adherent at 100% at baseline
Table 4 Rate of adherence among age group, gender and
viral load
Adherence at 24 weeks Adherence at 48 weeks
n EFV NVP n EFV NVP
Age group (years)
≤ 25 8 7.4% / 8 8% /
26–31 20 18.5% / 12 12% /
32–37 52 22.2% 33.3% 52 24% 35%
38–43 48 29.6% 19% 48 32% 20%
44–49 28 11.1% 19% 24 12% 15%
≥ 50 24 11.1% 14.2% 24 12% 15%
Gender
Male 80 50% 47.6% 76 36% 45%
Female 112 59.2% 52.3% 104 60% 55%
VFR 116 48.1% 76.1% 44 12% 40%
Abbreviation: EFV Efavirenz, NVP Nevirapine, VFR virological failure rate, n
number of patients
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macrocytosis measurements, visual analogue scales,
pill-counts and medication event monitoring systems
(MEMS) [6, 7, 9, 23, 24].
In this study, the proportion of patients with reduced
viral loads were found to be more adherent to ART and
consisted of patients in the age group ranging from 32
to 43 years. This could be because this population repre-
sents a more responsible set of individuals who may be
more organized and motivated in improving their health
and lifestyle. This result is in contrary to the findings
from a study performed to analyze adherence among older
HIV infected patients and in a prospective cohort study in
Cameroon. They reported that older patients (> 50
years) showed higher tolerance to ART and young pa-
tients (< 36 years) showed poorer adherence [22, 26].
Furthermore, females were better adherent to ART.
This could be due to the fact that women more often
attend health care fascilities, compared to men. Con-
sequently, a high proportion of women were repre-
sented in our study among those adherent to ART.
Limitations of the study include the loss to follow-up of
patients, as that might have influenced the efficacy of our
findings. In addition, we evaluated adherence based on
pharmacy records, on the number of patients who contin-
ued treatment, and did not investigate the correlation or
association between number of doses, adherence and viral
outcome. Our findings add evidence to the need of im-
proving strategies to evaluate adherence in HIV patients
on ART. Large cohort studies are needed to validate these
findings and evaluate the different methods used for asses-
sing adherence to ART. It is important to investigate the
various factors influencing adherence. The results from
these studies can be incorporated to enhance the manage-
ment of HIV infected individuals on ART.
Conclusion
Adherence and patient counselling play an important
role in maintaining successful ART outcomes. Ineffective
ART induces virological failure. There was a significant
decrease in the viral load suppression in both regimens.
The EFV regimen was more effective in suppressing viral
load and is less likely to induce a virological failure re-
sponse, compared to the NVP regimen.
Abbreviations
3TC: Lamivudine; ART: Antiretroviral therapy; AZT: Zidovudine; CSCCD: Center
for the Study and Control of Communicable Diseases;
EDTA: Ethylenediaminetetraacetic acid; EFV: Efavirenz; MEMS: Medication
event monitoring systems; NNRTIs: Non-nucleoside reverse transcriptase
inhibitors; NRTIs: Nucleoside reverse transcriptase inhibitors; NVP: Nevirapine;
RAMs: Resistance associated mutations; TDF: Tenofovir
Acknowledgements
This study was supported by the Center for the Study and Control of
Communicable Diseases (CSCCD) of the Faculty of Medicine and Biomedical
Sciences of the University of Yaoundé 1. Appreciation goes to all the
participants who took part in the study.
Funding
The study was supported by the CSCCD and received no external funding.
Availability of data and materials
The dataset used and/or analysed during the current study are found at the
CSCCD database and available from the corresponding author on reasonable
request.
Authors’ contributions
BHC and GMI: Development of research concept, recruitment of patients,
Laboratory analyses, interpretation of results and participated in the initial
draft of the manuscript. GBJ and AOMC: Development of research concept,
interpretation of results and drafting of manuscript. MM, ELY, AE and EL
contributed in laboratory analyses and drafting of the manuscript. All authors
read and approved the final version of the manuscript.
Ethics approval and consent to participate
Ethical approval was obtained from the Cameroon National Ethics
Committee for Human Health Research with reference number: N°2016/10/




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Center for the Study and Control of Communicable Diseases (CSCCD),
Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1,
Yaoundé, Cameroon. 2Division of Medical Virology, Department of Pathology,
Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg,
South Africa.
Received: 10 May 2018 Accepted: 15 February 2019
References
1. Pustil R. Global AIDS. Aids. 2016;17(Suppl 4):S3–11.
2. UNAIDS data 2017. Available online at: http://www.unaids.org/sites/default/
files/media_asset/20170720_Data_book_2017_en.pdf
3. Ministry of Health. National guideline on the prevention and management
of HIV in Cameroon, January 2015.
4. Pefura-YoneEW SE, Kengne AP, Balkissou AD, Kuaban C. Non-adherence to
antiretroviral therapy in Yaounde: prevalence, determinants and the
concordance of two screening criteria. J Infect Public Health. 2013;6:307–15.
5. World Health Organization. Consolidated guidelines on the use of
antiretroviral drugs for treating and preventing HIV infection:
Recommendation for a public health approach. (2016).
6. Nachega JB. Lower pill burden and once-daily antiretroviral treatment
regimens for HIV infection: a meta-analysis of randomized controlled trials.
Clin Infect Dis. 2014;58:1297–307.
7. Segeral O, madec Y, Ban B, Ouk V, Hak CR, Le Tiec C, et al. Simplified
assessment of antiretroviral adherence and prediction of virological efficacy
in HIV-infected patients in Cambodia. AIDS Res Treat. 2010. https://doi.org/
10.1155/2010/142076.
8. Fonsah JY, Njamnshi AK, Kouanfack C, Qiu F, Njamnshi DM, Tagny CT, et al.
Adherence to antiretroviral therapy (ART) in Yaoundé-Cameroon: association
with opportunistic infections, depression, ART regimen and side effects.
PLoS One. 2017;12:1–19.
9. Roux P, Kouanfack C, Cohen J, Marcellin F, Boyer S, Delaporte E, et al.
Adherence to antiretroviral treatment in HIV-positive patients in the
Cameroon context: promoting the use of medication reminder methods.
JAIDS. J Acquir Immune Defic Syndr. 2011;57:S40–3.
10. Meresse M, Carrien MP, Laurent C, Kouanfack C, Protopopescu C, Blanche J,
et al. Time patterns of adherence and long-term virological response to
Chendi et al. BMC Infectious Diseases          (2019) 19:194 Page 7 of 8
non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS
12110/ ESTHER trial in Cameroon. Antivir Ther. 2013;18:29–37.
11. Wu Y, Qiu Y, Yan P, Wang W, Xie M, Zia P, et al. Effectiveness of first-line
antiretroviral therapy in HIV/AIDS patients: a 5-year longitudinal evaluation
in Fujian Province, Southeast China. TT. Arch of Vir. 2015;160(11):2693–701.
12. Thompson MA. Antiretroviral Treatment of Adult HIV Infection. Jama. 2012;
308:387–402.
13. Tolle MA, Schwarzwald H, Calles NR. Antiretroviral Treatment. Retrieved
from https://bipai.org/sites/bipai/files/4-Antiretroviral-Treatment.pdf.
Accessed 10 May 2018.
14. Kouanfack C, Laurent C, Peytavin G, Ciaffi L, Ngolle M, Nkene YN, et al.
Adherence to antiretroviral therapy assessed by drug level monitoring and
self-report in Cameroon. J Acquir Immune Defic Syndr. 2008;48:216–9.
15. Dalal S, Holmes MD, Laurence C, Bajunirwe F, Guwatudde D, Njelekela M, et
al. Feasibility of a large cohort study in sub-Saharan Africa assessed through
a four-country study. Glob Health Action. 2015;8:1–10.
16. Teklu AM, Tsegaye E, Fekade D, Hailemelak A, Weiss W, Hassen E, et al.
Establishing a multicenter longitudinal clinical cohort study in Ethiopia:
advanced clinical monitoring of antiretroviral treatment project. Ethiop J
Health Sci. 2017;27(suppl 1):3–16.
17. Edwards JK, Cole SR, Martin JN, Moore R, Mathews WC, Kitahata, et al.
Dynamic visual display of treatment response in HIV-infected adults. Clin
Infect Dis. 2015;61:e1–4.
18. Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz
or nevirapine in three-drug combination therapy with two nucleoside-
reverse transcriptase inhibitors for initial treatment of HIV infection in
antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2016. https://
doi.org/10.1002/14651858.CD004246.
19. Castelnuovo B, Kiragga A, Mubiru F, Kambbuyu A, Kamya M, Reynolds SJ.
First-line antiretroviral therapy durability in a 10-year cohort of naïve adults
started on treatment in Uganda. J Int AIDS Soc. 2016;19:1–6.
20. Shearer K, Brennan AT, Maskew M, Long L, Berhanu R, Sanne I. The relation
between efavirenz versus nevirapine and virologic failure in Johannesburg,
South Africa. J Int AIDS Soc. 2014;17(1):–10.
21. Pillay P, Ford N, Shubber Z, Ferrand RA. Outcomes for Efavirenz versus
Nevirapine-containing regimens for treatment of HIV-1 infection: a
systematic review and Meta-analysis. PLoS One. 2013;8.
22. Zoufaly A, Jochum J, Hammerl R, Nassimi N, Raymond Y, burchard GD.
Virological failure after 1 year of first-line ART is not associated with HIV
minority drug resistance in rural Cameroon. J Antimicrob Chemother. 2015;
70:922–5.
23. Buscher A, Hartman C, Kallen MA, Giordano TP. Impact of antiretroviral
dosing frequency and pill burden on adherence among newly diagnosed,
HAART naïve, HIV patients. Int J STD AIDS. 2012;23(5):351–5. https://doi.org/
10.1258/ijsa.2011.011292.
24. Ochieng W, Kitawi RC, Nzomo TJ, Mwatelah RS, Kimulwo MJ, Ochieng DJ, et
al. Correlates of adherence and treatment failure among kenyan patients on
long term highly active antiretroviral therapy. J Acquir Immune Defic Syndr.
2015;69(2):e49–56.
25. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin
Infect Dis. 2000;30:S171–6.
26. Ghidei L, Simone M, Salow M, Zimmerman K, Paquin AM, Skarf M, et al.
Aging, antiretroviral and adherence: a meta analysis of adherence among
older hiv infected individuals. NIH-PA. 2013;30(10). https://doi.org/10.1007/
s40266-013-0107-7.
Chendi et al. BMC Infectious Diseases          (2019) 19:194 Page 8 of 8
